| Autor: |
ZHANG Zhendong, CAI Bin, WANG Hongwei, QIAO Zengyong |
| Jazyk: |
čínština |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Zhongguo quanke yixue, Vol 26, Iss 29, Pp 3665-3673 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1007-9572 |
| DOI: |
10.12114/j.issn.1007-9572.2023.0166 |
| Popis: |
Background The intestinal flora and its metabolites play an important role in the pathology of chronic heart failure (CHF), which is a severe manifestation or terminal stage of various cardiovascular diseases. Increasing evidence has shown that dysbiosis of the intestinal flora and its metabolites can lead to bacterial translocation, release of mediators, inflammatory response and consequently aggravation of CHF. Objective To analyze the changes of intestinal flora and its metabolite phenylacetylglutamine (PAGln) in patients with CHF and explore the role played by gut microbiota in heart failure. Methods A total of 58 patients with heart failure admitted to the Department of Cardiology of the South Branch of the Sixth People's Hospital of Shanghai Jiaotong University were selected as the CHF group, and 46 patients with the same CHF risk factors but without clinical symptoms and past medical history of CHF were selected as the control group from June 2021 to June 2022. Plotting ROC curves of brain natriuretic peptide (BNP) and PAGln for the diagnosis of CHF. The abundance and diversity of intestinal flora in the two groups were analyzed using 16S rRNA sequencing. Liquid chromatography with tandem mass spectrometry (LC-MS/MS) was used to detect PAGln concentrations in the plasma of samples from both two groups. Results The left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), BNP, and PAGln in the CHF group were higher than the control group, and the left ventricular ejection fraction (LVEF) was lower than the control group (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
